67 related articles for article (PubMed ID: 17570524)
1. A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients.
Curvo RP; Zalcberg IR; Scholl V; Pires V; Moellmann-Coelho A; Moreira MA
Leuk Res; 2008 Mar; 32(3):508-10. PubMed ID: 17570524
[No Abstract] [Full Text] [Related]
2. Supplemental results of the detection of splicing variant with c-ABL exon 7 deletion by direct sequencing Comment on "A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients" by Curvo et al. [Leuk. Res.].
Cho EH; Kang SK; Kim SY
Leuk Res; 2009 Mar; 33(3):505-6. PubMed ID: 18848355
[No Abstract] [Full Text] [Related]
3. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
[No Abstract] [Full Text] [Related]
4. Imatinib resistance in CML.
Volpe G; Panuzzo C; Ulisciani S; Cilloni D
Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
[TBL] [Abstract][Full Text] [Related]
5. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
Rodrigues MS; Sattler M
J Natl Cancer Inst; 2007 May; 99(9):662-3. PubMed ID: 17470729
[No Abstract] [Full Text] [Related]
6. Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.
Corm S; Biggio V; Roche-Lestienne C; Laï JL; Yakoub-Agha I; Philippe N; Nicolini FE; Facon T; Preudhomme C
Leukemia; 2005 Nov; 19(11):1991-2. PubMed ID: 16151468
[No Abstract] [Full Text] [Related]
7. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Ernst T; Erben P; Müller MC; Paschka P; Schenk T; Hoffmann J; Kreil S; La Rosée P; Hehlmann R; Hochhaus A
Haematologica; 2008 Feb; 93(2):186-92. PubMed ID: 18223278
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ
Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205
[TBL] [Abstract][Full Text] [Related]
10. Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia.
Yamamoto K; Yakushijin K; Nishikawa S; Minagawa K; Katayama Y; Shimoyama M; Matsui T
Cancer Genet Cytogenet; 2008 May; 183(1):77-81. PubMed ID: 18474303
[TBL] [Abstract][Full Text] [Related]
11. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG
Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868
[No Abstract] [Full Text] [Related]
12. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
[TBL] [Abstract][Full Text] [Related]
13. D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients.
Leguay T; Desplat V; Marit G; Mahon FX
Leukemia; 2005 Dec; 19(12):2332-3; author reply 2333-4. PubMed ID: 16281074
[No Abstract] [Full Text] [Related]
14. Applying the discovery of the Philadelphia chromosome.
Sherbenou DW; Druker BJ
J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
[TBL] [Abstract][Full Text] [Related]
15. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
Minami Y; Naoe T
Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
[TBL] [Abstract][Full Text] [Related]
16. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
18. Resistance and relapse with imatinib in CML: causes and consequences.
Deininger M
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S11-S21. PubMed ID: 18397677
[TBL] [Abstract][Full Text] [Related]
19. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
[TBL] [Abstract][Full Text] [Related]
20. Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients.
Joha S; Dauphin V; Leprêtre F; Corm S; Nicolini FE; Roumier C; Nibourel O; Grardel N; Maguer-Satta V; Idziorek T; Figeac M; Laï JL; Quesnel B; Etienne G; Guilhot F; Lippert E; Preudhomme C; Roche-Lestienne C
Leuk Res; 2011 Apr; 35(4):448-58. PubMed ID: 20684991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]